Perrigo (NYSE:PRGO) has been assigned a $107.00 target price by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 22.73% from the stock’s current price.
PRGO has been the subject of a number of other research reports. Deutsche Bank boosted their price objective on shares of Perrigo from $88.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, September 14th. Royal Bank of Canada reissued a “sell” rating and issued a $64.00 price objective on shares of Perrigo in a research note on Wednesday, September 13th. Canaccord Genuity reissued a “buy” rating and issued a $100.00 price objective (up previously from $88.00) on shares of Perrigo in a research note on Wednesday, September 13th. Wells Fargo & Company boosted their price objective on shares of Perrigo to $90.00 and gave the stock a “market perform” rating in a research note on Friday, November 10th. Finally, Jefferies Group reissued a “hold” rating and issued a $81.00 price objective on shares of Perrigo in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $92.13.
Shares of Perrigo (NYSE PRGO) traded up $0.65 during trading hours on Friday, hitting $87.18. The company’s stock had a trading volume of 609,000 shares, compared to its average volume of 1,676,453. Perrigo has a fifty-two week low of $63.68 and a fifty-two week high of $91.73. The stock has a market capitalization of $12,186.95, a price-to-earnings ratio of 17.66, a PEG ratio of 1.84 and a beta of 0.70. The company has a quick ratio of 1.24, a current ratio of 1.72 and a debt-to-equity ratio of 0.54.
In other Perrigo news, EVP John Wesolowski sold 450 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $83.09, for a total value of $37,390.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 1,051 shares of company stock worth $89,810. 6.90% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of PRGO. BB&T Securities LLC raised its holdings in Perrigo by 0.4% in the 2nd quarter. BB&T Securities LLC now owns 9,062 shares of the company’s stock valued at $684,000 after acquiring an additional 35 shares during the last quarter. State of Tennessee Treasury Department raised its holdings in Perrigo by 0.3% in the 2nd quarter. State of Tennessee Treasury Department now owns 39,214 shares of the company’s stock valued at $2,961,000 after acquiring an additional 103 shares during the last quarter. Sentry Investment Management LLC raised its holdings in Perrigo by 1.1% in the 2nd quarter. Sentry Investment Management LLC now owns 11,028 shares of the company’s stock valued at $833,000 after acquiring an additional 117 shares during the last quarter. Commonwealth Bank of Australia raised its holdings in Perrigo by 13.8% in the 2nd quarter. Commonwealth Bank of Australia now owns 1,455 shares of the company’s stock valued at $108,000 after acquiring an additional 176 shares during the last quarter. Finally, Geneva Advisors LLC raised its holdings in Perrigo by 4.7% in the 2nd quarter. Geneva Advisors LLC now owns 4,495 shares of the company’s stock valued at $339,000 after acquiring an additional 200 shares during the last quarter. 83.32% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This news story was reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/22/cantor-fitzgerald-reiterates-107-00-price-target-for-perrigo-prgo.html.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
